UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Nature reviews. Cancer, ISSN 1474-175X, 03/2005, Volume 5, Issue 3, pp. 172 - 183
Life Sciences & Biomedicine | Oncology | Science & Technology | Oncogene Proteins v-abl - pharmacology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Gene Expression Regulation, Neoplastic | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Proto-Oncogene Proteins c-abl - pharmacology | Animals | Cell Transformation, Neoplastic | Genes, abl | Antineoplastic Agents - pharmacology | Mice | Benzamides | Disease Models, Animal | Care and treatment | Translocation (Genetics) | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Hematopoietic stem cells | Index Medicus
Journal Article
Annals of hematology, ISSN 0939-5555, 04/2015, Volume 94, Issue 2, pp. 141 - 147
Chronic myeloid leukemia | Tyrosine kinase inhibitors | BCR-ABL1 | Philadelphia chromosome | Life Sciences & Biomedicine | Hematology | Science & Technology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Drug Resistance, Multiple | Voluntary Health Agencies | Europe | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Evidence-Based Medicine | Disease Progression | Fusion Proteins, bcr-abl - genetics | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Mutation | Drug Monitoring | Fusion Proteins, bcr-abl - metabolism | Practice Guidelines as Topic | Analysis | Leukemia | Stem cells | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2007, Volume 357, Issue 3, pp. 258 - 265
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Chromosome aberrations | Medical genetics | Dasatinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Piperazines - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Fusion Proteins, bcr-abl | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Adult | Female | Benzamides | Practice Guidelines as Topic | Protein-Tyrosine Kinases - antagonists & inhibitors | Case studies | Transplantation | Chronic myeloid leukemia | Health aspects | Stem cells | Bone marrow | Chromosomes | Leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 02/2009, Volume 113, Issue 8, pp. 1619 - 1630
Life Sciences & Biomedicine | Hematology | Science & Technology | Fusion Proteins, bcr-abl - genetics | Animals | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Molecular Biology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Signal Transduction - physiology | Fusion Proteins, bcr-abl - metabolism | Gene Expression Regulation, Leukemic - physiology | Index Medicus | Abridged Index Medicus | Review
Journal Article
Leukemia, ISSN 0887-6924, 08/2009, Volume 23, Issue 8, pp. 1432 - 1440
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Reactive Oxygen Species - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Oxidation-Reduction | Humans | NADPH Oxidases - antagonists & inhibitors | Neoplasm Proteins - physiology | RNA, Small Interfering - pharmacology | Glycogen Synthase Kinase 3 beta | Proto-Oncogene Proteins c-akt - physiology | NADPH Oxidase 4 | Onium Compounds - pharmacology | Glycogen Synthase Kinase 3 - metabolism | beta Catenin - metabolism | Hydrogen Peroxide - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Protein Phosphatase 1 - antagonists & inhibitors | Fusion Proteins, bcr-abl - physiology | Myeloid Cell Leukemia Sequence 1 Protein | NADPH Oxidases - genetics | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | Apoptosis - physiology | Cell Line, Tumor - metabolism | NADPH Oxidases - physiology | Cell proliferation | Cell lines | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Gene expression | Apoptosis | Index Medicus
Journal Article
Annals of hematology, ISSN 0939-5555, 04/2015, Volume 94, Issue 2, pp. 107 - 121
Signal transduction | Chronic myeloid leukaemia | Tyrosine kinase inhibitors | BCR-ABL | Philadelphia chromosome | Life Sciences & Biomedicine | Hematology | Science & Technology | Animals | Prognosis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Neoplasm Proteins - chemistry | Mutation | Neoplasm Proteins - genetics | Neoplasm Proteins - metabolism | Disease Progression | Leukemia | Cellular signal transduction | Stem cells | Index Medicus
Journal Article